Stocklytics Platform
Asset logo for symbol BPTH
Bio-Path Holdings
BPTH53
$0.82arrow_drop_up2.62%$0.02
Penny Stock
Asset logo for symbol BPTH
BPTH53

$0.82

arrow_drop_up2.62%

Performance History

Chart placeholder
Key Stats
Open$0.75
Prev. Close$0.79
EPS-8.34
DividendNon-Dividend
Next Earnings Date-
Dividend Yield %-
Market Cap$3.53M
PE Ratio-
LOWHIGH
Day Range0.77
0.85
52 Week Range0.65
21.60
Ratios
Revenue-
EBITDA Margin %-
EPS-8.34

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

•

Analyst Ratings

•
•

About Bio-Path Holdings (BPTH)

Bio-Path Holdings Inc. (BPTH) is a clinical and preclinical stage oncology-focused RNAi nanoparticle drug development company. The company is leveraging its proprietary DNAbilize RNAi nanoparticle technology to develop a pipeline of targeted nucleic acid cancer drugs. With a market capitalization of , Bio-Path Holdings Inc. operates in the biotechnology industry.
Bio-Path Holdings Inc. (BPTH) stock price history shows fluctuation over the years, reflecting market dynamics and investor sentiment. Investors can track the company's stock performance using the stock price history chart to make informed decisions. It is important to analyze financial data, news, and industry trends to better understand the stock's potential.
Websitecall_made
Sector
Healthcare
Industry
Biotechnology
CEO
Mr. Peter H. Nielsen MBA
Headquarters
Bellaire
Employees
10
Exchange
NASDAQ
add Bio-Path Holdings to watchlist

Keep an eye on Bio-Path Holdings

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
help

What is Bio-Path Holdings 's (BPTH) price per share?

The current price per share for Bio-Path Holdings (BPTH) is $0.82. The stock has seen a price change of $0.02 recently, indicating a 2.63% change. This reflects the stock's recent market performance and investor sentiment.
help

What is the 52-week high and low for Bio-Path Holdings (BPTH)?

For Bio-Path Holdings (BPTH), the 52-week high is $21.6, which is 2.53K% from the current price. The 52-week low is $0.65, the current price is 25.96% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.
help

Is Bio-Path Holdings (BPTH) a growth stock?

Bio-Path Holdings (BPTH) has shown an average price growth of -4.13% over the past three years. It has received a score of 21 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Bio-Path Holdings as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.
help

What is Bio-Path Holdings (BPTH) stock price performance year to date (YTD)?

As of the latest data, Bio-Path Holdings (BPTH) has a year-to-date price change of -91.68%. Over the past month, the stock has experienced a price change of -26.79%. Over the last three months, the change has been -35.43%. Over the past six months, the figure is -61.32%. Looking at a longer horizon, the five-year price change stands at -99.45%.
help

Is Bio-Path Holdings (BPTH) a profitable company?

Bio-Path Holdings (BPTH) has a net income of -$16.08M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of 0% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at , although specific revenue growth data is currently not available. Operating income is noted at -$15.84M. Furthermore, the EBITDA is -$12.98M.
help

What is the market capitalization of Bio-Path Holdings (BPTH)?

Bio-Path Holdings (BPTH) has a market capitalization of $3.53M. The average daily trading volume is 0.8, indicating the stock's liquidity and investor engagement.

News

Bio-Path Holdings Announces $4.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules
BIO-PATH HOLDINGS
PRIVATE PLACEMENT
FINANCING
BIOTECHNOLOGY
Oct 9, 2024

Bio-Path Holdings Announces $4.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules

Bio-Path Holdings to Present at H.C. Wainwright 26th Annual Global Investment Conference
BIO-PATH HOLDINGS
BIOTECHNOLOGY
RNAI NANOPARTICLE DRUGS
BLOOD CANCERS
SOLID TUMORS
Sep 3, 2024

Bio-Path Holdings to Present at H.C. Wainwright 26th Annual Global Investment Conference

Bio-Path Holdings Presents Data from Ongoing Phase 2 Combination Study of Prexigebersen for Treatment of Acute Myeloid Leukemia at European Hematology Association Congress
HEALTH
PRODUCT / SERVICES ANNOUNCEMENT
CLINICAL STUDY
Jun 14, 2024

Bio-Path Holdings Presents Data from Ongoing Phase 2 Combination Study of Prexigebersen for Treatment of Acute Myeloid Leukemia at European Hematology Association Congress

Bio-Path Holdings Announces Closing of $4.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules
HEALTH
CHANGES IN COMPANY'S OWN SHARES
Jun 5, 2024

Bio-Path Holdings Announces Closing of $4.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules

Bio-Path Holdings Presents Data from Ongoing Phase 2 Combination Study of Prexigebersen for Treatment of Acute Myeloid Leukemia at American Society of Clinical Oncology (ASCO) Annual Meeting
CLINICAL STUDY
Jun 3, 2024

Bio-Path Holdings Presents Data from Ongoing Phase 2 Combination Study of Prexigebersen for Treatment of Acute Myeloid Leukemia at American Society of Clinical Oncology (ASCO) Annual Meeting

Bio-Path Holdings to Present Data at 2024 European Hematology Association Congress
CALENDAR OF EVENTS
CLINICAL STUDY
May 24, 2024

Bio-Path Holdings to Present Data at 2024 European Hematology Association Congress

Take Your Investments to a Whole New Level